Does Cannabis Research Deserve As Much Funding As Ibogaine Research?

Cannabis research should receive funding on the scale of ibogaine research, because cannabis has broad therapeutic potential but requires a far more complex, plant-specific research approach. The piece connects Texas drug policy to research priorities, arguing that bills like Texas SB 3 have made cannabis research and medical cannabis access harder, while legislation supporting ibogaine therapy trials is positioned as a faster path because the compound is more pharmaceuticalizable and less formulation-dependent. The author outlines why cannabis funding would need multiple research tracks: studying cannabinoids beyond THC and CBD, mapping dose, exposure, formulation, and duration effects, advancing endocannabinoid system (ECS) research, establishing safety and harm reduction standards (including drug-drug interaction research), and building education and clinical research infrastructure. Overall, the argument is that treating cannabis science as a legitimate, evidence-driven medical field in Texas would better align policy with patient-centered care and long-term research realities.